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AGE, DEMENTIA, AND EVIDENCE-BASED MEDICATION USE AFTER ADMISSION
FOR ACUTE CORONARY SYNDROME
Lin CF1, Hsiao FY1, Wu FLL1, Bai CH2, Gau CS1, Shen LJ1
1National Taiwan University, Taipei, Taiwan, 2Taipei Medical University and Shin Kong WHS
Memorial Hospital, Taipei, Taiwan
OBJECTIVES: To assess the impact of dementia on evidence-based medication use
after admission for patients with acute coronary syndrome (ACS) across different
age groups.METHODS: Of 87,298 patients hospitalized for ACS between January 1,
2006 and December 31, 2007, 1835 patients with dementia and 3670 matched pa-
tients without dementia (1:2 ratio, matched by age, gender, and admitted hospital
level) were identified fromTaiwan’s National Health Insurance Research Database.
Use of evidence-based medications post-discharge were compared between pa-
tients with and without dementia across different age groups (65, 66-75, 76-85,
85). Multivariate logistic regression models were performed to examine the im-
pact of dementia on use of evidence-basedmedications.RESULTS:Overall, demen-
tia was associated with a 22% lower likelihood of use of evidence-based medica-
tions (adjusted odds ratio (OR)  0.78, CI0.68-0.89) in ACS patients. The use of
evidence-based medications decreased with age, and dementia worsened the uti-
lization. The proportions of patients receiving evidence-based medications were
85.6% (without dementia) versus 73.6% (with dementia) in the youngest age group
and 62.0 % (without dementia) versus 55.6% (with dementia) in the oldest age
group. CONCLUSIONS: Dementia and aging were associated with the use of evi-
dence-based medications in ACS patients.
CV3
REAL-WORLD CHARACTERIZATION OF HYPERTENSION PATIENTS IN JAPAN: A
1-YEAR OVERVIEW
Crawford B1, Ong SH2, Falvey H2
1Adelphi Values, Tokyo, Japan, 2Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: To characterize the real-world profile of hypertension patients in
Japan and their treatments, BP control, and health care resource consumptionwith
a primary focus on isolated systolic hypertension (ISH) and the elderly patient
population. METHODS: Data were extracted from insurance claims and from an-
nual health examination. Only subjects who had blood pressure readings from
their annual health examinations in 2009 and 2010 at 10-14 months apart were
included. Subjects were identified by ICD-10-CM. Treatments were evaluated to
understand the current distributions with a focus on 65 versus 65 years of age.
Control rates were calculated and costs evaluated by hypertension type. RESULTS:
A total of 9269 subjects were identified with a hypertension diagnosis and annual
health exam blood pressure readings. Subjects mean age was 51.61(9.54) years old,
72.6% were male, and were diagnosed for 3.72(3.95) years. 56.24% were currently
controlled and 15.48% had ISH. Poly-pharmacy for hypertension was common
(42.49%). ARBs (47.68%) and CCBs (28.26%) were usedmost frequently. The number
of treatments subjects received increased with the number of years diagnosed,
with an average of 1.23medicationswithin the first year and 2.45 after 10 years. For
subjects controlled at baseline, 21.6% reverted to “uncontrolled” 1-year later and
47.9% ISH subjects improved “to-goal”. The average cost of treating subjects signif-
icantly differed over one year: JPY231,626.32 for “controlled” subjects,
JPY230,989.37 for ISH and isolated diastolic subjects were least expensive at
JPY141,739.55. Elderly had a significantly higher cost than subjects less than 65-
year-old (JPY266,771.28 vs JPY213,091.42). CONCLUSIONS:Hypertension in Japan is
characterized by poly-pharmacy and only moderate control. Elderly patients are
significantly more costly to treat and “controlled” and ISH patients were the most
costly to treat. Treatment was dominated by ARBs and CCBs (alone or in combina-
tion with other treatments).
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ASSOCIATION BETWEEN KNOWLEDGE AND HEALTH RELATED QUALITY OF
LIFE? IS PATIENT EDUCATION ALWAYS BENEFICIAL?
Saleem F1, Hassali MA1, Shafie AA1, Aljadhey H2, Haq N1, Atif M3
1Universiti Sains Malaysia, Penang, Malaysia, 2King Saud University, Riyadh, Riyadh, Saudi
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OBJECTIVES: To evaluate association between HRQoL and knowledge among hy-
pertensive population of Pakistan. METHODS: A cross sectional descriptive study
was undertakenwith a representative cohort of hypertension patients. Using prev-
alence based sampling technique, a total of 385 hypertensive patients were se-
lected from two public hospitals of Quetta city, Pakistan. Hypertension Fact Ques-
tionnaire (HFQ) and European Quality of Life scale (EQ-5D) were used for data
collection. SPSS v 16.0 was used to compute descriptive analysis of patients’ demo-
graphic and disease related information. Categorical variables were described as
percentages while continuous variables were expressed as mean standard devi-
ation (SD). Spearman’s rho co-relation was used to identify the association be-
tween study variables. RESULTS: The mean (SD) age of the patients was 39.02 
(6.59), with 68.8% males (n265). The mean (SD) duration of hypertension was
3.010.93 years. Forty percent (n154) had bachelor degree with 34.8% (n134)
working in private sector. Almost forty one percent (n140) hadmonthly income of
more than 15000 Pakistan rupees (Pk Rs) per month (1 Pk Rs0.01172 US$) with
75.1% (n289) having urban residency. The mean EQ-5D descriptive score
(0.460.28) and EQ-VAS score (63.976.62) indicated lower HRQoL in our study
participants. Mean knowledge score was 8.03  0.42. Correlation coefficient be-
tween HRQoL and knowledge was 0.208 (p 0.001), indicating a week positive
association. CONCLUSIONS: Results of this study highlight hypertension knowl-
edge to be weakly associated with HRQoL suggesting that imparting knowledge to
patients do not necessarily improve HRQoL. More attention should be given to
identify individualized factors affecting HRQoL.
PODIUM SESSION II:
HEALTH CARE EXPENDITURES STUDIES
EX1
THE EFFECTS OF POLYPHARMACY ON HEALTH CARE COSTS AND HOSPITAL
ADMISSIONS IN THAI ELDERLY POPULATION: MULTIVARIATE TWO-PART
MODELS
Sruamsiri R1, Jeanpeerapong N2, Jampachaisri K3, Chaiyakunapruk N1
1Center of Pharmaceutical Outcomes Research, Muang, Phitsanulok, Thailand, 2Department of
Pharmacy, Muang, Phitsanulok, Thailand, 3Department of Mathematics, Muang, Phitsanulok,
Thailand
OBJECTIVES: Polypharmacy is a widely known risk factor for adverse drug reac-
tions, drug-drug interactions, and low adherence in the elderly population. There
remains a paucity of evidence demonstrating its effect on hospital admissions and
costs. This study aims to determine the effects of polypharmacy on hospital ad-
missions and hospital costs among older patients in Thailand.METHODS: A retro-
spective cohort study was conducted using an electronic patient database in a
provincial hospital of Thailand . All patients aged 60 years or older with at least 2
visits during 2009 were included. Exposure of interest is polypharmacy and exces-
sive polypharmacy which were defined as dispensed medications for more than
five and ten items, respectively. Outcomes of interest are hospital admissions and
hospitalization costs incurred after index date of polypharmacy. We performed
two-partmodel and used poisson regression and log-transformed linear regression
with Duan’s smearing estimator to determine the effects of polypharmacy on hos-
pital admissions rate and hospitalization costs, respectively. All analyses were
adjusted for potential confounders and propensity score. RESULTS: A total of
17,787 elderly patients were included. Themean agewas 71 years with 57% female.
Forty-two and 12 percent of patients received polypharmacy and excessive polyp-
harmacy, respectively. Excessive polypharmacy was significantly associated with
increased risk of admission (adjusted incidence rate ratio (IRR): 3.2 (95% CI; 1.1-5.4))
while only increased trend of admission was found among polypharmacy (IRR: 1.5
(95% CI; 0.9-2.1), Hospitalization costs were significantly higher at $135 (95% CI;
111.0 – 159.0) and $25.0 (95% CI; 16.1 – 38.0) for excessive polypharmacy and polyp-
harmacy, compared with non-polypharmacy. CONCLUSIONS: Both polypharmacy
and excessive polypharmacy have significantly elevated health care costs but only
excessive polypharmacy is significantly associated with increased risk of hospital
admission. These findings demonstrated the detrimental effects of polypharmacy
and highlighted the importance of finding measures to reduce polypharmacy.
EX2
AN OBSERVATION ON THE TREND OF OUTPATIENT CLINIC UTILIZATION AND
NUMBERS OF MEDICAL PRESCRIPTION GIVEN IN TAIWAN ELDERLY BETWEEN
1997 AND 2010
Hung YN1, Yang SY2, Wang TC3, Chen IJ1, Yu S1
1National Yang-Ming University, Taipei, Taiwan, 2Taipei City Psychiatric Center, Taipei City
Hospital, Taipei, Taiwan, 3Taipei City Hospital, Taipei, Taiwan
OBJECTIVES: To know the changes of outpatient clinic utilization and the prescrip-
tion numbers per each outpatient clinic visit. METHODS: This study use Longitu-
dinal Health Insurance Database(LHID) 2005 from the National Health Insurance
Research Database, it contains 1 million random samples of year 2005 Registry.
There are approximately 25.68 million individuals in this registry. The study sub-
jects were the elderly over 65 years old in each year. We had reviewed the preva-
lence of outpatient clinic visit during the year, average outpatient clinic visit per
year, medicine prescription in outpatient clinic of our study subjects. (grouped as
numbers of item prescribed; zero, one to four, five to nine and above ten items).
RESULTS: The total numbers of study subjects in each year increase from 52,672 in
1997 to 108,444 in 2010. Most of the elderly had utilized outpatient clinic, and the
percentage of clinic utilization during these years had been in a rise every year.
(93.4% in 1997 versus 96.8% in 2010). For those who had utilized at least one time
outpatient clinic resources, the average outpatient visit numbers in this study
ranges from25.6 to 31.3 times/person-year during the period. However, numbers of
prescription in each visit had decreased gradually. In 1997, the percentages of no
items prescribed, 1-4 items, 5-9 items and more than 10 items prescribed were
50.1%, 28.39%, 20.07% and 1.42% respectively. In 2010, however, the percentages
were 53.4%, 33.54%, 12.3% and 0.79% respectively.CONCLUSIONS:The prescription
numbers had decreased gradually in the study period. The utilization percentage of
outpatient clinic, however, was on a rise. In addition, multiple prescriptions (more
than 5 items) was quiet common in our study,medical care givers should paymore
attention on the issue of multiple prescription of our elderly.
EX3
A EVALUATION OF THE EFFECTS FROM CHINA DRUG POLICY REFORM DURING
2009-2011: SOME SUCCESS, MANY UNINTENDED EFFECTS
Guan Q1, Cai J2, Dummett H3, Tan SC1
1Double Helix Consulting, Asia-Pacific, Singapore, Singapore, 2China Europe International
Business School, Shanghai, China, 3Double Helix Consulting, London, UK
OBJECTIVES: Many drug policies were implemented during 2009-2011 in China in
order to lower the health cost burden from drug over-consumption and over-pric-
ing. The effects of these polices have been intensively debated at the turn of 2012 in
the mainstream media, albeit in the absence of comprehensive official statistics.
The aim of this research is to assess the outcome of the drug policy reform during
2009-2011, based on the available publications. METHODS: Drug policies issued
2009-2011 by central governmentwere identified and grouped intomutually exclu-
sive categories, based on their main targets. All relevant news reports published in
mainstream Chinese digital news portals from December 2011 to March 2012 were
gathered and analysed by health policy trained analyst familiar with Chinese
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health policy issues. The effects of each policy category were disentangled into
Price, Volume and Quality; and where an effect was identifiable, by comparing to
the intent of the policy, it was qualified by 3 sets of parameters: Direct-or-Indirect
Effect, Desired-or-Undesired Effect and Decreasing-or-Increasing Effect. RESULTS:
The identified 10 policies were grouped into 5 main categories: Essential Drug
Listing & Price Control (3), Essential Drug Usage Promotion (2), Reimbursed Drug
Listing & Price Control (2), Hospital Drug Price Controls (2), and Prescribing-Dis-
pensing Separation (1). The majority (4/5) of the policy categories were targeted
directly at lowering drug prices, and did achieve certain Direct-Desired-Decreasing
effects on Price. Three of these four policy categories, however, also had indirect-
undesired effects, mainly manifested as encouraging over-prescribing or lowering
drug quality. The other policy aimed at promoting rational pharmaceutical pre-
scribing failed to make tangible impact at national level. CONCLUSIONS: The drug
policies implemented during 2009-2011 achieved limited success and new ap-
proaches towards reform will be needed to obtain better results.
EX4
RECENT TRENDS IN COMMUNITY PHARMACY PAYMENT OF NATIONAL
HEALTH INSURANCE IN SOUTH KOREA
Choi SE1, Cheong C2, Lee H2, Kim J2, Lim EA1
1Korea University, Yeongi-gun, Chungnam, South Korea, 2Seoul National University, Seoul, South
Korea
OBJECTIVES: To investigate recent trends in reimbursement payment for phar-
macy service and pharmaceuticals from the Korean National Health Insurance
(NHI) using the NHI claims database. METHODS: Pharmacy claims data were ex-
tracted from the Korean NHI database from January 1, 2008 to March 31, 2011 by
quarterly unit. The monthly number of prescriptions of each pharmacy, the aver-
age number of supply-days per prescription, and payment amount to each phar-
macy including cost of pharmaceuticals and dispensing fees were calculated from
the claims. The information of all community pharmacies such as the number of
pharmacists in practice and pharmacy locationwas collected. The trends and vari-
ation in the pharmacy payment amount and the composition were traced on quar-
terly basis. RESULTS: Total claims of 15,996 pharmacies were included for analysis.
The monthly reimbursed payment per pharmacy increased from 29.73 million
Korean Won (KW) in 1Q 2008 to 36.41 million KW in 1Q 2011. While the increase
related to dispensing fees was 1.73 million KW per pharmacy for this period, the
amount contributing to pharmaceuticals increased from4.95million KW. The daily
number of prescriptions per pharmacist was ranged from 39.41 in 2008/3Q to 51.09
in 2009/4Q, which is below the current daily threshold for the discount of dispens-
ing fee in South Korea, 75 prescriptions per pharmacist. The average number of
supply-days per prescription was ranged from 9.12 in 2008/1Q to 11.32 in 2010/3Q.
CONCLUSIONS: While the number of prescriptions per pharmacist and supply-
days of prescriptions were relatively stable, the reimbursement amount per phar-
macy showed an increasing trend. The main source of the increase seemed to be
the payment for pharmaceuticals rather than pharmacy services.
PODIUM SESSION II:
HEALTH TECHNOLOGY ASSESSMENT STUDIES
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COST-EFFECTIVENESS ANALYSIS OF BONE MINERAL DENSITY SCREENING TOOLS
Kang E1, Lee BK2
1Soonchunhyang University, Asan City, South Korea, 2Soonchunhyang University, Cheonan City,
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OBJECTIVES: The aim of this study was to compare the cost effectiveness of BMD-
(Bone Mineral Density) screening tools- RA, QUS, pDXA, QCT, and DXA, for wom-
en’s lifetime bone densitometry exam at 66 years old. METHODS: A total of 101
subjects aged in 60s’ were recruited to estimate sensitivity and specificity of each
BMD screening tool. A Markov model was developed to analyze the cost-effective-
ness of DXA, QUS, RA, pDXA, and QCT. A cohort of 10,000 women aged 66 was
constructed for each bone densitometry and a cohort of 10,000women aged 66was
also constructed as a non-exam group. In theMarkovmodel of osteoporosis and its
related fractures, costs and effectiveness measured by QALY were estimated until
the cohorts reached 100 years old or died. It was assumed that only costs were
discounted by 5% and the compliance for osteoporosis drugs was 38%. Sensitivity
analysis was performed on the discount rate and the compliance to osteoporosis
drugs. RESULTS: ICER (incremental cost-effectiveness ratio) is an indicator of how
much extra costs are needed to increase an extra 1QALY compared to the reference
group. The magnitudes of ICER’s were ordered as DXApDXA(QCT, RA, QUS).
DXA and pDXA cost extra 398,618 won and 453,947 won, respectively, in order to
increase 1 extra QALY compared to the non-exam group, which meant that DXA
and pDXA were very cost-effective. The extra costs for QUS, RA, and QCT to in-
crease 1 QALY compared to the non-exam group ranged 530,000 won‘590,000 won,
which meant that these were also cost-effective. CONCLUSIONS: All the BMD
screening tools that were examined in this study were found to be cost-effective in
terms of ICER. When the relative cost-effectiveness of pDXA, QUS, RA, and QCT
compared with DXA, DXA was predominant over the other.
HT3
DEVELOPMENT OF A CHECK LIST FOR QUALITY ASSESSMENT OF
PHARMACOECONOMIC EVALUATIONS SUBMITTED FOR REIMBURSEMENT IN
TAIWAN
Wu GHM1, Liao CH1, Shau WY1, Lo PC1, Pwu RF2
1Center for Drug Evaluation, Taipei, Taiwan, 2Taipei Medical University, Taipei, Taipei, Taiwan
OBJECTIVES: It is not mandatory for pharmaceutical manufacturers to submit
cost-effectiveness evidence yet in Taiwan, but an incentive of a maximum 10%
mark-up for conducting local cost-effectiveness analysis has been announced
since 2010. HTA/CDE (Division of Health Technology Assessment, Center for Drug
Evaluation) assists the assessment on the strength of evidence of local cost-effec-
tiveness evaluation, and a checklist was therefore developed to ensure the consis-
tency and to improve the transparency. This study presents the impact of local
pharmacoeconomic incentive and the development of the checklist.METHODS: By
reviewing other international checklists for quality assessment of pharmacoeco-
nomic evidence and adding items for local adaptation and transferability, a check-
list consisting of four dimensions including PICOS, cost-effectiveness analysis de-
sign, source of parameters, and overall quality was developed with a four-level-
grading for evidence strength. The local pharmacoeconomic evidence was
identified from the dossiers submitted by themanufacturers during 2008-2011, and
was independently assessed by the four reviewers in the economic evaluation
team of HTA/CDE as reference cases. Discrepancies between reviewers were dis-
cussed until consensus was reached. RESULTS: There were 83 and 67 dossiers
submitted for reimbursement before and after the incentive was announced, re-
spectively. However, no local pharmacoeconomic evidence has been submitted
until eight months after the incentive was announceed. Another four dossiers
consist of five local pharmacoeconomic evaluation (one with multiple indications)
were submitted in 2011. The strengths of evidencewere graded as strong,medium,
low, and very low for 0, 1, 2, and 3 cases according to the checklist. CONCLUSIONS:
A pragmatic strategy was used to incorporate cost-effectiveness evidence into the
drug reimbursement decisions in Taiwan. Local pharmacoeconomic evidence sub-
missions increase slowly after the incentive was announced. A quality assessment
checklist was proposed. Further experience will be cumulated and discussed
among the submitting bodies, the appraisal committee members, and HTA/CDE.
HT4
HEALTH TECHNOLOGY ASSESSMENT MAP IN ASIA – REGIONAL VERSUS
INTERNATIONAL INFLUENCES
Andreykiv M1, Wiebinga C1, Gabel C2, Zorzi O1
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Singapore, Singapore
OBJECTIVES: To gain insights into health technology assessments (HTA) landscape
in Asia and to better understand international influence dynamics across intercon-
nected HTA universe. METHODS: Information on major Asian HTA agencies
(NECA, HITAP, CDE, etc) was collected and analysed at the level of four data cate-
gories: agencies, institutions, people (members) and assessments. For each cate-
gory a number of attributes were included (such as location, affiliations, member-
ships, type of technology, decision on technology). The Ni3 softwarewas applied to
add multiple types of connections between the datasets to conduct the analysis
and visualize HTA networks. The tool enabled mapping of relationship links that
represent direction and weight of influence, overlaying displayed stakeholders
with visual charts summarizing sets of quantitative values (such as number of
employees or budget) for visual patternmatching and comparison, and geographic
analysis. RESULTS: The analysis revealed the initiated collaboration between HTA
stakeholders in the Asia region. In the centre of the Asian HTA ecosystem are
located the most established agencies in Korea, Taiwan and Thailand where HTA
already yields important evidence to inform policy and practice. The visual analy-
sis revealed patterns of collaboration where agencies were 1) referring to each
other; 2) referring to the same sources and academic institutions, and 3) absorbing
the experience from well-established European HTA agencies such as NICE or
IQWIG. CONCLUSIONS: HTA has expanded globally and can be characterised by
common patterns in interactions when looking at and refining the evidence re-
quired for the reimbursment. Rapidly growing in number and in influence HTA
organizations in Asia are strengthening their abilities through collaboration with
each other, by involving independent research institutions into the HTA process
and by building upon European HTA experience.
PODIUM SESSION II:
PREFERENCE-BASED OUTCOMES STUDIES
PR1
DOES MEDICATION ADHERENCE CORRELATE WITH HEALTH-RELATED
QUALITY OF LIFE? FINDINGS FROM A DESCRIPTIVE ANALYSIS
Saleem F1, Hassali MA1, Shafie AA1, Aljadhey H2, Haq N1, Atif M3
1Universiti SainsMalaysia, Penang, Malaysia, 2King Saud University, Riyadh, Riyadh, Saudi Arabia,
3Allianze University College of Medical Sciences (AUCMS), Penang, Malaysia
OBJECTIVES: To evaluate the association between medication adherence and
Health Related Quality of Life (HRQoL) among hypertension patients in Quetta city,
Pakistan. METHODS: A questionnaire based cross sectional study design was un-
dertakenwith hypertension patients attending public hospitals in Quetta city, Pak-
istan. HRQoLwasmeasured by Euroqol EQ-5D.Medication adherencewas assessed
by Drug Attitude Inventory. Descriptive statistics was used to tabulate demo-
graphic and disease related information. Spearman’s correlation was used to as-
sess the association between the study variables. All analysis was performed by
using SPSS 17.0. RESULTS: Among 385 study patients, mean age (SD) was 39.02
(6.59), with 68.8% of males dominating the entire cohort. Mean (SD) duration of
hypertension was 3.010.939 years. Forty percent (n154) had bachelor level of
education with 34.8% (n134) working in the private sector. Negative and weak
correlation (-0.77) between medication adherence and EQ-5D was reported. In ad-
dition, negative week but significant correlation (-0.120, p0.019) was observed
among medication adherence and EQ-VAS. CONCLUSIONS: No apparent relation-
ship between medication adherence and HRQoL was reported. Improved medica-
tion adherence therefore in patients with hypertension does not necessarily im-
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